228 related articles for article (PubMed ID: 14734600)
21. [Antianginal drugs].
Kugiyama K; Yasue H
Nihon Rinsho; 1994 Jul; 52 Suppl(Pt 1):1051-8. PubMed ID: 12436657
[No Abstract] [Full Text] [Related]
22. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Murphy SA; Budaj A; Varshavsky S; Wolff AA; Skene A; McCabe CH; Braunwald E;
JAMA; 2007 Apr; 297(16):1775-83. PubMed ID: 17456819
[TBL] [Abstract][Full Text] [Related]
23. Clinical experience with ranolazine in a veteran population with chronic stable angina.
Reeder DN; Gillette MA; Franck AJ; Frohnapple DJ
Ann Pharmacother; 2012 Jan; 46(1):42-50. PubMed ID: 22215689
[TBL] [Abstract][Full Text] [Related]
24. [Late sodium current and calcium overload--pathogenesis and adequate treatment].
Jacobshagen C
Dtsch Med Wochenschr; 2013 Apr; 138(16):842-7. PubMed ID: 23589047
[No Abstract] [Full Text] [Related]
25. Management of chronic stable angina pectoris.
Rodríguez-Ospina L; Montano-Soto L
Bol Asoc Med P R; 2008; 100(4):39-47. PubMed ID: 19400528
[TBL] [Abstract][Full Text] [Related]
26. Ranolazine. A metabolic modulator for the treatment of chronic stable angina.
Anderson JR; Nawarskas JJ
Cardiol Rev; 2005; 13(4):202-10. PubMed ID: 15949056
[TBL] [Abstract][Full Text] [Related]
27. At the dawn of a new era in treating angina pectoris, or just another antianginal drug? Some considerations about ranolazine.
Bălan H
Rom J Intern Med; 2010; 48(4):361-9. PubMed ID: 21528766
[TBL] [Abstract][Full Text] [Related]
28. [Therapeutic application of myocardial cytoprotection].
Ribeiro C
Rev Port Cardiol; 1994 Sep; 13(9):669-70. PubMed ID: 7818940
[No Abstract] [Full Text] [Related]
29. Evolving treatment strategies for chronic refractory angina.
Yang EH; Barsness GW
Expert Opin Pharmacother; 2006 Feb; 7(3):259-66. PubMed ID: 16448320
[TBL] [Abstract][Full Text] [Related]
30. Comparative Effectiveness of Ranolazine Versus Traditional Therapies in Chronic Stable Angina Pectoris and Concomitant Diabetes Mellitus and Impact on Health Care Resource Utilization and Cardiac Interventions.
Page RL; Ghushchyan V; Read RA; Hartsfield CL; Koch BR; Nair KV
Am J Cardiol; 2015 Nov; 116(9):1321-8. PubMed ID: 26358510
[TBL] [Abstract][Full Text] [Related]
31. Spotlight on ranolazine in chronic stable angina pectoris.
Siddiqui MA; Keam SJ
Am J Cardiovasc Drugs; 2006; 6(5):357-9. PubMed ID: 17083271
[TBL] [Abstract][Full Text] [Related]
32. Metabolic antianginal agent ranolazine offers good symptom relief in a patient with inoperable severe aortic stenosis.
Athauda-Arachchi P; Lang C
Cardiovasc Ther; 2012 Aug; 30(4):e210-1. PubMed ID: 21884008
[TBL] [Abstract][Full Text] [Related]
33. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.
Lee L; Horowitz J; Frenneaux M
Eur Heart J; 2004 Apr; 25(8):634-41. PubMed ID: 15084367
[TBL] [Abstract][Full Text] [Related]
34. [Drugs in angina pectoris].
Koster RW
Ned Tijdschr Geneeskd; 1987 Nov; 131(48):2174-7. PubMed ID: 2891049
[No Abstract] [Full Text] [Related]
35. Ranolazine: a review of its use in chronic stable angina pectoris.
Keating GM
Drugs; 2008; 68(17):2483-503. PubMed ID: 19016575
[TBL] [Abstract][Full Text] [Related]
36. [Conservative therapy of patients with stable coronary heart disease].
Custodis F; Laufs U
Herz; 2012 Feb; 37(1):85-96. PubMed ID: 22331062
[TBL] [Abstract][Full Text] [Related]
37. Metabolic therapeutics in angina pectoris: history revisited with perhexiline.
Inglis S; Stewart S
Eur J Cardiovasc Nurs; 2006 Jun; 5(2):175-84. PubMed ID: 16469541
[TBL] [Abstract][Full Text] [Related]
38. Clinical and Economic Outcomes of Ranolazine Versus Conventional Antianginals Users Among Veterans With Chronic Stable Angina Pectoris.
Bress AP; Dodson JA; King JB; Sauer BC; Reese T; Crook J; Radwanski P; Knippenberg K; Greene T; Nelson RE; Munger MA; Weintraub WS; LaFleur J
Am J Cardiol; 2018 Dec; 122(11):1809-1816. PubMed ID: 30292334
[TBL] [Abstract][Full Text] [Related]
39. Beta-Blockers and Calcium Channel Blockers: First Line Agents.
Pascual I; Moris C; Avanzas P
Cardiovasc Drugs Ther; 2016 Aug; 30(4):357-365. PubMed ID: 27576497
[TBL] [Abstract][Full Text] [Related]
40. [Anti-ischemia drug therapy].
Dubach P; Ratti R
Ther Umsch; 1991 Aug; 48(8):549-54. PubMed ID: 1681596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
